Inhibikase Therapeutics (NYSE:IKT) Price Target Cut to $23.00 by Analysts at HC Wainwright

Inhibikase Therapeutics (NYSE:IKT) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.87) EPS, FY2025 earnings at ($1.47) EPS and FY2026 earnings at ($1.46) EPS.

Inhibikase Therapeutics Trading Down 1.1 %

IKT opened at $1.81 on Tuesday. Inhibikase Therapeutics has a 52-week low of $0.79 and a 52-week high of $4.35. The business’s 50-day simple moving average is $1.88 and its 200 day simple moving average is $1.78.

Inhibikase Therapeutics (NYSE:IKT) last posted its quarterly earnings results on Wednesday, March 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative return on equity of 147.03%. As a group, research analysts predict that Inhibikase Therapeutics will post -1.87 earnings per share for the current year.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.